Related Experiment Video
Updated: Sep 24, 2025
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Effectiveness and Safety of Baidu Jieduan Granules for COVID-19: A Retrospective Observational Multicenter Study
Xiang-Ru Xu1, Wen Zhang1, Xin-Xin Wu1
1Department of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
Insights
Baidu Jieduan Granules (BDJDG) demonstrated effectiveness in treating common coronavirus disease 2019 (COVID-19), with a high discharge rate and no serious adverse events. This traditional Chinese medicine shows promise for managing COVID-19 symptoms and recovery.
Area of Science:
- Integrative Medicine
- Infectious Diseases
- Pharmacology
Background:
- Coronavirus disease 2019 (COVID-19) poses a significant global health challenge.
- Effective and safe treatments are crucial for managing common COVID-19 cases.
- Traditional Chinese Medicine (TCM) offers potential therapeutic options.
Purpose of the Study:
- To evaluate the efficacy and safety of Baidu Jieduan Granules (BDJDG) for treating common COVID-19.
- To assess the impact of BDJDG on disease progression and patient recovery.
- To investigate the effect of BDJDG on key clinical and laboratory markers in COVID-19 patients.
Main Methods:
- A multicenter, retrospective, observational clinical trial involving 230 common COVID-19 patients.
- Patients received BDJDG combined with conventional Western medicine over 28 days.
- Subgroup analysis based on supplemental oxygen use (mild and moderate groups).
Main Results:
- High discharge rate (95.7%) and low disease progression rate (4.3%) by day 28.
- Significant reduction in median nucleic acid conversion time (12 days) and hospitalization duration (15 days).
- Rapid symptom subsidence for fever, cough, and fatigue, with high recovery rates; no serious adverse events reported.
Conclusions:
- Baidu Jieduan Granules (BDJDG) appears to be an effective and safe treatment for common COVID-19.
- BDJDG may contribute to faster recovery and improved clinical outcomes.
- Further prospective studies are warranted to confirm these findings.
Objective:
To evaluate the effectiveness and safety of Baidu Jieduan Granules (BDJDG) to treat common type coronavirus disease 2019 (COVID-19).
Methods:
This multicenter, retrospective, and observational clinical trial included 230 common COVID-19 patients in Leishenshan, Huangshi, and Laohekou Hospitals in Wuhan from January 21 to March 26, 2020. The included patients were further divided into two subgroups according to the use of supplemental oxygen, mild and moderate groups. During the first 14 d of hospitalization, all patients were administered BDJDG combined with conventional Western medicine, and observed for continuous 28 d. Primary outcomes were disease progression rate and discharge rate. Secondary outcomes included negative conversion time of nucleic acid, hospitalization duration, clinical symptom subsidence time, and symptom regression rate.
Results:
A total of 230 common COVID-19 patients were analyzed (138 in moderate group and 92 in mild group). By day 28, the disease progression rate was 4.3% and the discharge rate was 95.7%. All mild cases recovered and were discharged from hospital. The median negative conversion time of nucleic acid of all 230 COVID-19 patients was 12 d [inter-quartile range (IQR) 3.5-17], the median hospitalization duration was 15 d (IQR 12-20). The median time to fever, cough, and fatigue recovery was 4 d (IQR 2-6), 8 d (IQR 5-12), and 8 d (IQR 5-11). The recovery rate of fever, cough, and fatigue was 94.6%, 90.5%, and 93.5%. The median time to clinical improvement was 12 d (IQR 10-17). Compared with the baseline, total leukocyte counts, neutrophil counts, lymphocyte counts, and platelet counts were increased significantly on days 7 and 14 (P<0.01). C-reactive protein markedly increased on day 3 and significantly decreased on days 7 and 14 (P<0.01). No serious adverse events occurred during treatment.
Conclusion:
BDJDG may be effective and safe for treatment of common type COVID-19. (Registration No. ChiCTR2000030836).
